Li and colleagues developed and produced a novel bispecific antibody, BsAb-5, that effectively targets c-MET and CTLA-4 in lung cancer stem cell (LCSC)-like cells with a high degree of specificity and affinity. Here, MET is linked to lung carcinoma.